Skip to main content
Erschienen in: Diabetologia 6/2010

01.06.2010 | Article

Impact of metabolic indices on central artery stiffness: independent association of insulin resistance and glucose with aortic pulse wave velocity

verfasst von: D. R. Webb, K. Khunti, R. Silverman, L. J. Gray, B. Srinivasan, P. S. Lacy, B. Williams, M. J. Davies

Erschienen in: Diabetologia | Ausgabe 6/2010

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

Non-invasive measures of aortic stiffness reflect vascular senescence and predict outcome in diabetes. Glucose-mediated elastic artery sclerosis may play an integral role in the development of macrovascular complications. We used carotid–femoral pulse wave velocity (cfPWV) to quantify independent associations of fasting glucose, post-challenge glucose and derived insulin resistance (HOMA-IR) with aortic stiffness.

Methods

cfPWV was measured using a 4 MHz continuous wave Doppler ultrasound probe within groups with newly identified age- and sex-matched normal glucose metabolism (NGM), impaired glucose regulation (IGR) and diabetes mellitus populations (n = 570, mean age 59.1, 56% male).

Results

After multivariate adjustment, IGR and diabetes were associated with significant aortic stiffening compared with NGM (adjusted cfPWV±SE: NGM, 9.15 ± 0.12 m/s; IGR 9.76 ± 0.11 m/s, p < 0.001; diabetes, 9.89 ± 0.12 m/s, p < 0.001). IGR stratification indicated that impaired fasting glucose (IFG; 9.71 ± 0.12 m/s) and post-challenge (impaired glucose tolerance; 9.82 ± 0.24 m/s) categories had similar cfPWV (p = 0.83). Modelled predictors of cfPWV were used to assess independent metabolic associations with arterial stiffness. Fasting glucose concentration (β = 0.10; 95% CI 0.05, 0.18; p = 0.003), 2 h post-challenge glucose (β = 0.14; 95% CI 0.02, 0.23; p < 0.001) and HOMA-IR (β = 0.20, 95% CI 0.05, 0.53; p < 0.001) were independently related to cfPWV after adjustment for age, sex, mean arterial pressure, heart rate, body mass index, renal function and antihypertensive medication.

Conclusions/interpretation

IGR characterised by fasting or post-challenge hyperglycaemia is associated with significant vascular stiffening. Post-challenge glucose and HOMA-IR are the most powerful metabolic predictors of arterial stiffness, implying hyperglycaemic excursion and insulin resistance play important roles in the pathogenesis of arteriosclerosis.
Literatur
1.
Zurück zum Zitat Coutinho M, Gerstein HC, Wang Y, Yusuf S (1999) The relationship between glucose and incident cardiovascular events. A meta regression analysis of published data from 20 studies of 95, 783 individuals followed for 12.4 years. Diabetes Care 22:233–240CrossRefPubMed Coutinho M, Gerstein HC, Wang Y, Yusuf S (1999) The relationship between glucose and incident cardiovascular events. A meta regression analysis of published data from 20 studies of 95, 783 individuals followed for 12.4 years. Diabetes Care 22:233–240CrossRefPubMed
2.
Zurück zum Zitat DECODE Study Group, on behalf of the European Diabetes Epidemiology Group (2001) Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 161:397–405CrossRef DECODE Study Group, on behalf of the European Diabetes Epidemiology Group (2001) Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 161:397–405CrossRef
3.
Zurück zum Zitat Cruickshank K, Riste L, Anderson SG, Wright JS, Dunn G, Gosling RG (2002) Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: an integrated index of vascular function? Circulation 106:2085–2090CrossRefPubMed Cruickshank K, Riste L, Anderson SG, Wright JS, Dunn G, Gosling RG (2002) Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: an integrated index of vascular function? Circulation 106:2085–2090CrossRefPubMed
4.
Zurück zum Zitat Satoh N, Ogawa Y, Usui T et al (2003) Anti-atherogenic effect of pioglitazone in type 2 diabetes patients irrespective of the responsiveness to its anti-diabetic effect. Diabetes Care 26:2493–2499CrossRefPubMed Satoh N, Ogawa Y, Usui T et al (2003) Anti-atherogenic effect of pioglitazone in type 2 diabetes patients irrespective of the responsiveness to its anti-diabetic effect. Diabetes Care 26:2493–2499CrossRefPubMed
5.
Zurück zum Zitat Rahman S, Ismail AA, Ismail SB, Naing NN, Abdul Rahman AR (2007) Effect of rosiglitazone/ramipril on preclinical vasculopathy in newly diagnosed, untreated diabetes and IGT patients: 1-year randomised, double-blind, placebo-controlled study. Eur J Clin Pharmacol 63:733–741CrossRefPubMed Rahman S, Ismail AA, Ismail SB, Naing NN, Abdul Rahman AR (2007) Effect of rosiglitazone/ramipril on preclinical vasculopathy in newly diagnosed, untreated diabetes and IGT patients: 1-year randomised, double-blind, placebo-controlled study. Eur J Clin Pharmacol 63:733–741CrossRefPubMed
6.
Zurück zum Zitat Dilaveris P, Giannopoulos G, Riga M, Synetos A, Stefanadis C (2007) Beneficial effects of statins on endothelial dysfunction and vascular stiffness. Curr Vasc Pharmacol 5:227–237CrossRefPubMed Dilaveris P, Giannopoulos G, Riga M, Synetos A, Stefanadis C (2007) Beneficial effects of statins on endothelial dysfunction and vascular stiffness. Curr Vasc Pharmacol 5:227–237CrossRefPubMed
7.
Zurück zum Zitat Nakamura T, Fujii S, Hoshino J et al (2005) Selective angiotensin receptor antagonism with valsartan decreases arterial stiffness independently of blood pressure lowering in hypertensive patients. Hypertens Res 28:937–943CrossRefPubMed Nakamura T, Fujii S, Hoshino J et al (2005) Selective angiotensin receptor antagonism with valsartan decreases arterial stiffness independently of blood pressure lowering in hypertensive patients. Hypertens Res 28:937–943CrossRefPubMed
8.
Zurück zum Zitat Henry RM, Kostense PJ, Spijkerman AM et al (2003) Arterial stiffness increases with deteriorating glucose tolerance status: the Hoorn Study. Circulation 107:2089–2095CrossRefPubMed Henry RM, Kostense PJ, Spijkerman AM et al (2003) Arterial stiffness increases with deteriorating glucose tolerance status: the Hoorn Study. Circulation 107:2089–2095CrossRefPubMed
9.
Zurück zum Zitat Schram MT, Henry RM, van Dijk RA et al (2004) Increased central artery stiffness in impaired glucose metabolism and type 2 diabetes: the Hoorn Study. Hypertension 43:176–181CrossRefPubMed Schram MT, Henry RM, van Dijk RA et al (2004) Increased central artery stiffness in impaired glucose metabolism and type 2 diabetes: the Hoorn Study. Hypertension 43:176–181CrossRefPubMed
10.
Zurück zum Zitat Raham S, Ismail AA, Ismail SB, Naing NN, Rahman AR (2008) Early manifestation of macrovasculopathy in newly diagnosed never treated type II diabetic patients with no traditional CVD risk factors. Diabetes Res Clin Pract 80:253–258CrossRef Raham S, Ismail AA, Ismail SB, Naing NN, Rahman AR (2008) Early manifestation of macrovasculopathy in newly diagnosed never treated type II diabetic patients with no traditional CVD risk factors. Diabetes Res Clin Pract 80:253–258CrossRef
11.
Zurück zum Zitat van Dijk RA, Nijpels G, Twisk JW et al (2000) Change in common carotid artery diameter, distensibility, and compliance in subjects with a recent history of impaired glucose tolerance: a 3-year follow-up study. J Hypertens 18:293–300CrossRefPubMed van Dijk RA, Nijpels G, Twisk JW et al (2000) Change in common carotid artery diameter, distensibility, and compliance in subjects with a recent history of impaired glucose tolerance: a 3-year follow-up study. J Hypertens 18:293–300CrossRefPubMed
12.
Zurück zum Zitat Ohnishi H, Saitoh S, Takagi S et al (2003) Pulse wave velocity as an indicator of atherosclerosis in impaired fasting glucose: the Tanno and Sobetsu Study. Diabetes Care 26:437–440CrossRefPubMed Ohnishi H, Saitoh S, Takagi S et al (2003) Pulse wave velocity as an indicator of atherosclerosis in impaired fasting glucose: the Tanno and Sobetsu Study. Diabetes Care 26:437–440CrossRefPubMed
13.
Zurück zum Zitat van Popele NM, Hak EA, Mattace-Raso FU et al (2006) Impaired fasting glucose is associated with increased arterial stiffness in elderly people without diabetes mellitus: the Rotterdam Study. J Am Geriatr Soc 54:397–404CrossRefPubMed van Popele NM, Hak EA, Mattace-Raso FU et al (2006) Impaired fasting glucose is associated with increased arterial stiffness in elderly people without diabetes mellitus: the Rotterdam Study. J Am Geriatr Soc 54:397–404CrossRefPubMed
14.
Zurück zum Zitat Czernichow S, Bertrais S, Blacher J et al (2005) Metabolic syndrome in relation to structure and function of large arteries: a predominant effect of blood pressure—a report from the SU.VI.MAX. Vascular Study. Am J Hypertens 18:1154–1160CrossRefPubMed Czernichow S, Bertrais S, Blacher J et al (2005) Metabolic syndrome in relation to structure and function of large arteries: a predominant effect of blood pressure—a report from the SU.VI.MAX. Vascular Study. Am J Hypertens 18:1154–1160CrossRefPubMed
15.
Zurück zum Zitat Ahluwalia N, Drouet L, Ruidavets J et al (2006) Metabolic syndrome is associated with markers of subclinical atherosclerosis in a French population-based sample. Atherosclerosis 186:345–353CrossRefPubMed Ahluwalia N, Drouet L, Ruidavets J et al (2006) Metabolic syndrome is associated with markers of subclinical atherosclerosis in a French population-based sample. Atherosclerosis 186:345–353CrossRefPubMed
16.
Zurück zum Zitat Ferreira I, Boreham CA, Twisk JR et al (2007) Clustering of metabolic syndrome risk factors and arterial stiffness in young adults: the Northern Ireland Young Hearts Project. J Hypertens 25:1009–1020CrossRefPubMed Ferreira I, Boreham CA, Twisk JR et al (2007) Clustering of metabolic syndrome risk factors and arterial stiffness in young adults: the Northern Ireland Young Hearts Project. J Hypertens 25:1009–1020CrossRefPubMed
17.
Zurück zum Zitat Nakanishi N, Suzuki K, Tatara K (2003) Clustered features of the metabolic syndrome and the risk for increased aortic pulse wave velocity in middle-aged Japanese men. Angiology 54:551–559CrossRefPubMed Nakanishi N, Suzuki K, Tatara K (2003) Clustered features of the metabolic syndrome and the risk for increased aortic pulse wave velocity in middle-aged Japanese men. Angiology 54:551–559CrossRefPubMed
18.
Zurück zum Zitat Schillaci G, Pirro M, Vaudo G et al (2005) Metabolic syndrome is associated with aortic stiffness in untreated essential hypertension. Hypertension 45:1078–1082CrossRefPubMed Schillaci G, Pirro M, Vaudo G et al (2005) Metabolic syndrome is associated with aortic stiffness in untreated essential hypertension. Hypertension 45:1078–1082CrossRefPubMed
19.
Zurück zum Zitat Safar ME, Thomas F, Blacher J et al (2006) Metabolic syndrome and age-related progression of aortic stiffness. J Am Coll Cardiol 47:72–75CrossRefPubMed Safar ME, Thomas F, Blacher J et al (2006) Metabolic syndrome and age-related progression of aortic stiffness. J Am Coll Cardiol 47:72–75CrossRefPubMed
20.
Zurück zum Zitat The ADVANCE Collaborative (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358:2560–2572CrossRef The ADVANCE Collaborative (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358:2560–2572CrossRef
21.
Zurück zum Zitat The Action to Control Cardiovascular Risk in Diabetes Study Group (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358:2545–2559CrossRef The Action to Control Cardiovascular Risk in Diabetes Study Group (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358:2545–2559CrossRef
22.
Zurück zum Zitat Duckworth W, Abraira C, Moritz T et al (2009) Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360:129–139CrossRefPubMed Duckworth W, Abraira C, Moritz T et al (2009) Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360:129–139CrossRefPubMed
23.
Zurück zum Zitat Goodarzi MO, Psaty BM (2008) Glucose lowering to control macrovascular disease in type 2 diabetes: treating the wrong surrogate end point? JAMA 300:2051–2053CrossRefPubMed Goodarzi MO, Psaty BM (2008) Glucose lowering to control macrovascular disease in type 2 diabetes: treating the wrong surrogate end point? JAMA 300:2051–2053CrossRefPubMed
24.
Zurück zum Zitat Yki-Jarvinen H, Westerbacka J (2007) Insulin resistance, arterial stiffness and wave reflection. Adv Cardiol 44:252–260CrossRefPubMed Yki-Jarvinen H, Westerbacka J (2007) Insulin resistance, arterial stiffness and wave reflection. Adv Cardiol 44:252–260CrossRefPubMed
25.
Zurück zum Zitat Sengstock DM, Vaitkevicius PV, Supiano MA (2005) Arterial stiffness is related to insulin resistance in nondiabetic hypertensive older adults. J Clin Endocrinol Metab 90:2823–2827CrossRefPubMed Sengstock DM, Vaitkevicius PV, Supiano MA (2005) Arterial stiffness is related to insulin resistance in nondiabetic hypertensive older adults. J Clin Endocrinol Metab 90:2823–2827CrossRefPubMed
26.
Zurück zum Zitat Salomaa V, Riley W, Kark JD, Nardo C, Folsom AR (1995) Non-insulin-dependent diabetes mellitus and fasting glucose and insulin concentrations are associated with arterial stiffness indexes: the ARIC Study. Circulation 91:1432–1443PubMed Salomaa V, Riley W, Kark JD, Nardo C, Folsom AR (1995) Non-insulin-dependent diabetes mellitus and fasting glucose and insulin concentrations are associated with arterial stiffness indexes: the ARIC Study. Circulation 91:1432–1443PubMed
27.
Zurück zum Zitat Van Dijk RAJM, Bakker SJL, Scheffer PG, Heine RJ, Stehouwer CDA (2003) Associations of metabolic variables with arterial stiffness in type 2 diabetes mellitus: focus on insulin sensitivity and postprandial triglyceridaemia. Eur J Clin Invest 33:307–315CrossRefPubMed Van Dijk RAJM, Bakker SJL, Scheffer PG, Heine RJ, Stehouwer CDA (2003) Associations of metabolic variables with arterial stiffness in type 2 diabetes mellitus: focus on insulin sensitivity and postprandial triglyceridaemia. Eur J Clin Invest 33:307–315CrossRefPubMed
28.
Zurück zum Zitat Laurent S, Cockcroft J, van Bortel L et al (2006) Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 27:2588–2605CrossRefPubMed Laurent S, Cockcroft J, van Bortel L et al (2006) Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 27:2588–2605CrossRefPubMed
29.
Zurück zum Zitat Davies MJ, Webb DR, Srinivasan B et al (2008) Does screening work for the common good? ADDITION-Leicester: design of a multi-factorial intervention trial in an ethnically diverse population with screen-detected type 2 diabetes. Diabetologia 51(Suppl 1):S426 (Abstract) Davies MJ, Webb DR, Srinivasan B et al (2008) Does screening work for the common good? ADDITION-Leicester: design of a multi-factorial intervention trial in an ethnically diverse population with screen-detected type 2 diabetes. Diabetologia 51(Suppl 1):S426 (Abstract)
30.
Zurück zum Zitat Webb DR, Khunti K, Srinivasan B et al. (2010) Rationale and design of the ADDITION-Leicester study, a systematic screening programme and randomised controlled trial of multi-factorial cardiovascular risk intervention in people with type 2 diabetes mellitus detected by screening. Trials. doi:10.1186/1745-6215-11-16 Webb DR, Khunti K, Srinivasan B et al. (2010) Rationale and design of the ADDITION-Leicester study, a systematic screening programme and randomised controlled trial of multi-factorial cardiovascular risk intervention in people with type 2 diabetes mellitus detected by screening. Trials. doi:10.​1186/​1745-6215-11-16
31.
Zurück zum Zitat Sandbaek A, Griffin SJ, Rutten G et al (2008) Stepwise screening for diabetes identifies people with high but modifiable coronary heart disease risk—the ADDITION-Europe Study. Diabetologia 51:1127–1134CrossRefPubMed Sandbaek A, Griffin SJ, Rutten G et al (2008) Stepwise screening for diabetes identifies people with high but modifiable coronary heart disease risk—the ADDITION-Europe Study. Diabetologia 51:1127–1134CrossRefPubMed
32.
Zurück zum Zitat Mancia G, de Backer G, Dominiczak A et al (2007) 2007 ESH-ESC practice guidelines for the management of arterial hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens 25:1751–1762CrossRefPubMed Mancia G, de Backer G, Dominiczak A et al (2007) 2007 ESH-ESC practice guidelines for the management of arterial hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens 25:1751–1762CrossRefPubMed
34.
Zurück zum Zitat World Health Organization (1999) Definition, diagnosis and classification of diabetes and its complications. A report of a WHO consultation. Part 1: Diagnosis and Classification of Diabetes Mellitus World Health Organization (1999) Definition, diagnosis and classification of diabetes and its complications. A report of a WHO consultation. Part 1: Diagnosis and Classification of Diabetes Mellitus
35.
Zurück zum Zitat Matthews DR, Hosker JP, Rudenski AS (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419CrossRefPubMed Matthews DR, Hosker JP, Rudenski AS (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419CrossRefPubMed
36.
Zurück zum Zitat Lambers Heerspink HJ, Brinkman JW, Bakker SJ, Gansevoort RT, de Zeeuw D (2006) Update on microalbuminuria as a biomarker in renal and cardiovascular disease. Curr Opin Nephrol Hypertens 15:631–636CrossRefPubMed Lambers Heerspink HJ, Brinkman JW, Bakker SJ, Gansevoort RT, de Zeeuw D (2006) Update on microalbuminuria as a biomarker in renal and cardiovascular disease. Curr Opin Nephrol Hypertens 15:631–636CrossRefPubMed
37.
Zurück zum Zitat Morita S, Kasayama S, Otsuki M et al (2006) Atherosclerotic risk factors in Japanese subjects with isolated impaired fasting glucose and those with isolated impaired glucose tolerance according to 1997 and 2003 American Diabetes Association criteria. Diabetes Care 29:2123–2126CrossRefPubMed Morita S, Kasayama S, Otsuki M et al (2006) Atherosclerotic risk factors in Japanese subjects with isolated impaired fasting glucose and those with isolated impaired glucose tolerance according to 1997 and 2003 American Diabetes Association criteria. Diabetes Care 29:2123–2126CrossRefPubMed
38.
Zurück zum Zitat Wakabayashi I, Masuda H (2006) Association of acute-phase reactants with arterial stiffness in patients with type 2 diabetes mellitus. Clin Chim Acta 365:230–235CrossRefPubMed Wakabayashi I, Masuda H (2006) Association of acute-phase reactants with arterial stiffness in patients with type 2 diabetes mellitus. Clin Chim Acta 365:230–235CrossRefPubMed
39.
Zurück zum Zitat Aronson D (2003) Cross-linking of glycated collagen in the pathogenesis of arterial and myocardial stiffening of ageing and diabetes. J Hypertens 21:3–12CrossRefPubMed Aronson D (2003) Cross-linking of glycated collagen in the pathogenesis of arterial and myocardial stiffening of ageing and diabetes. J Hypertens 21:3–12CrossRefPubMed
40.
Zurück zum Zitat Airaksinen KE, Salela PI, Linnaluoto MK, Ikaheimo MJ, Anola K, Rynanen LJ (1993) Diminished arterial elasticity in diabetes: association with fluorescent advanced glycosylation end products in collagen. Cardiovasc Res 27:942–945CrossRefPubMed Airaksinen KE, Salela PI, Linnaluoto MK, Ikaheimo MJ, Anola K, Rynanen LJ (1993) Diminished arterial elasticity in diabetes: association with fluorescent advanced glycosylation end products in collagen. Cardiovasc Res 27:942–945CrossRefPubMed
41.
Zurück zum Zitat Stehouwer CDA, Henry RMA, Ferreira I (2008) Arterial stiffness in diabetes and the metabolic syndrome: a pathway to cardiovascular disease. Diabetologia 51:527–529CrossRefPubMed Stehouwer CDA, Henry RMA, Ferreira I (2008) Arterial stiffness in diabetes and the metabolic syndrome: a pathway to cardiovascular disease. Diabetologia 51:527–529CrossRefPubMed
42.
Zurück zum Zitat Jialal I, Miguelino E, Griffen SC, Devaraj S (2007) Concomitant reduction of low-density lipoprotein-cholesterol and biomarkers of inflammation with low-dose simvastatin therapy in patients with type 1 diabetes. J Clin Endocrinol Metab 92:3136–3140CrossRefPubMed Jialal I, Miguelino E, Griffen SC, Devaraj S (2007) Concomitant reduction of low-density lipoprotein-cholesterol and biomarkers of inflammation with low-dose simvastatin therapy in patients with type 1 diabetes. J Clin Endocrinol Metab 92:3136–3140CrossRefPubMed
43.
Zurück zum Zitat Weber T, Ammer M, Rammer M et al (2009) Non-invasive determination of carotid-femoral pulse wave velocity depends critically on assessment of travel distance: a comparison with invasive measurement. J Hypertens 27:1624–1630CrossRefPubMed Weber T, Ammer M, Rammer M et al (2009) Non-invasive determination of carotid-femoral pulse wave velocity depends critically on assessment of travel distance: a comparison with invasive measurement. J Hypertens 27:1624–1630CrossRefPubMed
44.
Zurück zum Zitat Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW (2008) 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359:1577–1589CrossRefPubMed Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW (2008) 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359:1577–1589CrossRefPubMed
Metadaten
Titel
Impact of metabolic indices on central artery stiffness: independent association of insulin resistance and glucose with aortic pulse wave velocity
verfasst von
D. R. Webb
K. Khunti
R. Silverman
L. J. Gray
B. Srinivasan
P. S. Lacy
B. Williams
M. J. Davies
Publikationsdatum
01.06.2010
Verlag
Springer-Verlag
Erschienen in
Diabetologia / Ausgabe 6/2010
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-010-1689-9

Weitere Artikel der Ausgabe 6/2010

Diabetologia 6/2010 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.